Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844925 | 0.90 | HTT (0.43) | HTTLMNAALDH1A1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL844116 | 0.88 | HTT (0.42) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL16743438 | 0.81 | HTT (0.57) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL16743427 | 0.77 | LMNA (0.48) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL240843 | 0.73 | SMYD3 (0.39) | HTTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL842547 | 0.73 | HTT (0.52) | HTTLMNAALDH1A1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL844765 | 0.72 | HTT (0.51) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL16998580 | 0.71 | MEN1 (0.57) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL16998578 | 0.71 | MEN1 (0.57) | HTTLMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL844462 | 0.71 | HTT (0.46) | HTTLMNAALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | HTT 4119/4885LMNA 2913/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.